Side-by-side comparison of AI visibility scores, market position, and capabilities
Future pairs members with 130+ expert human coaches at $199/month using Apple Watch biometrics; 4.9-star rated app with $108M raised ($75M Series C). Founded 2017, San Francisco.
Future was founded in 2017 in San Francisco with the mission of making expert personal training accessible to anyone, not just athletes or the wealthy who can afford in-person coaching. The company built a digital personal training platform that pairs each member with a dedicated human coach who designs individualized workout plans, monitors progress through Apple Watch biometric data, and provides real-time feedback through the app. Future's core philosophy is that accountability and personalization — not generic content — are what actually drive sustained behavior change and fitness results.\n\nFuture's platform pairs members with more than 130 expert coaches who have backgrounds in strength and conditioning, sports performance, and clinical exercise science. Coaches review member activity daily, adjust programming based on recovery and performance data, and communicate directly through the app — creating a relationship-driven coaching model at digital scale. The service is priced at $199 per month, positioning it as a premium alternative to both in-person personal training and algorithm-driven fitness apps. Future integrates deeply with Apple Watch to capture heart rate, workout metrics, and activity data, giving coaches objective performance signals to inform programming decisions.\n\nFuture has raised $108 million in total, including a $75 million Series C, and maintains a 4.9-star rating in the App Store across tens of thousands of reviews — a remarkable signal of member satisfaction in a category often plagued by high churn. The company's human-plus-AI coaching model occupies a distinct position between the low-cost digital fitness market and the high-cost in-person coaching market, and its 130-plus coach network gives it a proprietary talent asset that is difficult to replicate. As demand for personalized health and longevity programs grows among high-income professionals, Future's model scales coach capacity through AI-assisted tools while preserving the relational quality that drives retention.
Franklin Lakes NJ medical technology (NYSE: BDX) at $21.8B FY2025 revenue (+8.2%); $17.5B Reverse Morris Trust spinoff with Waters (2025), Edwards critical care acquisition $4.2B (2024) competing with Baxter for infusion systems.
Becton, Dickinson and Company (BD) is a Franklin Lakes, New Jersey-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BDX) as an S&P 500 Health Care component — manufacturing and selling medical supplies, devices, laboratory equipment, and diagnostic products through approximately 74,000 employees serving healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers in over 190 countries. In fiscal year 2025 (ended September 30, 2025), BD reported full-year revenue of $21.8 billion (up 8.2% year-over-year) with Q4 FY2025 revenue of $5.9 billion (+8.3% reported, +3.9% organic growth), and declared a quarterly dividend of $1.05 per share (+1%). Founded in 1897 in New York City by Maxwell Becton and Fairleigh Dickinson Sr. as a thermometer and surgical instrument maker, BD has grown through 125+ years of acquisitions to become a Fortune 500 ($21.8B revenue, #211 on 2024 Fortune 500) global medtech leader. The company operates through three segments: BD Medical (~50% of revenue, IV catheters, syringes, prefillable drug delivery systems, and medication management solutions), BD Life Sciences (flow cytometry, microbiology, molecular diagnostics, and lab automation), and BD Interventional (advanced patient monitoring, interventional cardiology, and peripheral vascular interventions). BD invests $1.2+ billion annually in R&D. In 2024, BD acquired Edwards Lifesciences' critical care monitoring unit for $4.2 billion.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.